Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK’s NICE Not Convinced By Cannabis-Based Medicines

Executive Summary

New draft guidance from the health technology assessment body NICE says that more evidence is needed on cannabis-based medicines before they can be more widely used. In the meantime, it says they should not be used in chronic pain, epilepsy or spasticity in multiple sclerosis, while nabilone may be used for chemotherapy-related sickness.

You may also be interested in...



England’s NICE Backs Epidyolex For Seizures, Sativex For MS Spasticity

Health technology assessment body NICE has given the thumbs-up to Epidyolex and Sativex, which become the first plant-derived medicinal cannabis products to secure routine NHS funding. It has also issued positive guidance on other products including nabilone, but turned down the use of cannabis-based drugs in chronic pain.

GW Gets Two Cannabis-Based Meds Backed By NICE

Two cannabis-based drugs developed by GW Pharmaceuticals have been approved for use on the NHS in England for the first time and will be prescribed to patients with epilepsy and multiple sclerosis.

GW Still Sees Future For Sativex In US

The UK firm is starting an additional Phase III trial of 450 patients to supplement positive data from the three European Phase III trials it has already concluded in a bid to convince the FDA of Sativex's potential.

Related Content

Topics

UsernamePublicRestriction

Register

PS140654

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel